Genome machine learning company Deep Genomics is using artificial intelligence to develop drugs to tackle diseases related to gene defects. Several other companies are seeking to apply machine learning to drug development. The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses, making it an ideal for developing highly-targeted drugs. DeepMind has already developed a drug that targets mutations in one of the most common genetic disorders affecting children, called Batten disease.
Genome machine learning company Deep Genomics is using artificial intelligence to develop drugs to tackle diseases related to gene defects. The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses, making it an ideal for developing highly-targeted drugs. DeepMind has already developed a drug that targets mutations in one of the most common genetic disorders affecting children, called Batten disease.